Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesHigh-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistanceTailored targeted therapy for all: a realistic and worthwhile objective?Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeHigh-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancerAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Novel points of attack for targeted cancer therapy.Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study.HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
P2860
Q26743510-CBB686D9-1A27-4F59-98C8-0ED89E0D0F91Q28474284-18044F0B-9DB1-486A-886B-F6D49B7D1A3FQ33555473-7DC64F09-66D5-454B-A4A6-7CB443C943E3Q33745113-AD197429-9167-40C6-9D4B-F6DD7744A89CQ34048024-F7041E23-4FC5-4AB3-8097-0EE0B4EFB9A5Q34743488-B02DC610-C9D3-40A9-B0A7-E2187C0167B4Q35023279-320229F1-CC23-44BF-99C6-A343451D5E96Q35029573-42C6B623-A34F-4B55-9271-7029ADC5615BQ35087728-5CCE7704-3D13-4C6E-B7A1-BBEE9E784223Q36087126-DC6FD796-3AA9-4014-8F1D-BC064576632AQ37040549-E308FF2D-0BC5-40AA-ADCC-C489B4188B88Q37822734-9D7F7CD7-0009-4112-8F73-84B3305763DCQ39528312-C1536B7C-31D6-4380-8503-DE5E062EA071Q39932632-5BA832FE-415A-4849-BD64-21DACAD67CF3Q42486311-11FCE90C-8C16-4293-80B8-28898F0342A2Q48250667-6C2BCD12-D1D1-4F64-988C-AA12DB9D1B5BQ54519232-A13D769C-EEC4-40A3-B830-57B338488AD4Q54550048-40FB7EAC-B63C-404B-9649-660232E9FFFDQ55396428-F80BAC18-E2F1-461D-82E8-669A4F5A6517
P2860
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcome of patients with early ...... ction of HER2 and TOP2A status
@en
Outcome of patients with early ...... tion of HER2 and TOP2A status.
@nl
type
label
Outcome of patients with early ...... ction of HER2 and TOP2A status
@en
Outcome of patients with early ...... tion of HER2 and TOP2A status.
@nl
prefLabel
Outcome of patients with early ...... ction of HER2 and TOP2A status
@en
Outcome of patients with early ...... tion of HER2 and TOP2A status.
@nl
P2093
P2860
P356
P1476
Outcome of patients with early ...... ction of HER2 and TOP2A status
@en
P2093
Allen Gown
Charles Haskell
Charles Shapiro
Daniel F Hayes
Eric Swain
G Thomas Budd
George Sledge
James Ingle
Kathy S Albain
P2860
P304
P356
10.1200/JCO.2008.20.1566
P407
P577
2009-07-20T00:00:00Z